MannKind Buys scPharmaceuticals For $360 Million Bet: Can This Transform Its Future In Cardiorenal Care?

In reviewing MannKind Corporation’s latest financial performance and strategic initiatives, the company presents a nuanced investment outlook characterized by both opportunities and challenges. MannKind reported a revenue increase of 6% year-over-year for the second quarter of 2025, with $77 million in total, and $155 million year-to-date, marking a 12% growth compared to the previous year. This growth was primarily driven by Tyvaso DPI royalties, which rose by 22%, contributing $31 million in the second quarter. MannKind’s endocrine business unit also showed a strong performance, notably Afrezza, which grew 13% yearover-year in the quarter to reach $18 million, underpinned by a 22% increase in new prescriptions in the first half of the year.